凯莱英(002821) - 2018 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders rose by 37.21% to CNY 104,230,871.71 for the current period[7] - Operating revenue grew by 29.86% to CNY 447,324,504.83 for the current period[7] - Basic earnings per share increased by 42.42% to CNY 0.47[7] - The net profit after deducting non-recurring gains and losses increased by 49.76% to CNY 101,239,522.40 for the current period[7] - Net profit attributable to the parent company was ¥260,898,703.74, reflecting a 30% increase from ¥200,765,764.29 in the previous year[16] - Net profit for the period was CNY 246,203,162.56, compared to CNY 216,865,622.76 in the previous period, reflecting an increase of approximately 13.5%[47] - The company’s total profit for the period was CNY 273,650,721.53, compared to CNY 261,715,908.05 in the previous period, representing an increase of about 4.0%[47] - The net profit for the quarter reached CNY 5,039,312.01, compared to CNY 2,641,574.48 in the same period last year, indicating a significant increase of approximately 90.5%[51] Revenue and Costs - Total operating revenue for the period reached CNY 1,204,962,585.97, an increase from CNY 895,938,102.03 in the previous period, representing a growth of approximately 34.4%[46] - Total operating costs amounted to CNY 955,352,003.10, up from CNY 684,142,364.61, indicating a rise of about 39.6%[46] - Total operating costs amounted to ¥354,961,388.42, up 37.5% from ¥258,148,730.95 in the prior period[37] Assets and Liabilities - Total assets increased by 11.28% to CNY 2,934,721,034.79 compared to the end of the previous year[7] - The total assets of the company reached 2,934.72 million RMB, an increase from 2,637.20 million RMB at the beginning of the period[32] - The total liabilities as of October 31, 2018, are 537.06 million RMB, up from 482.17 million RMB at the beginning of the period[32] - The company's total assets decreased to ¥1,419,338,527.44 from ¥1,444,943,970.32 at the beginning of the period, reflecting a decline of 1.8%[35] - Total liabilities decreased to ¥154,042,800.25 from ¥176,561,039.62, a reduction of 12.8%[36] Cash Flow - The net cash flow from operating activities decreased significantly by 87.46% to CNY 11,867,206.27[7] - Cash flow from operating activities amounted to CNY 273,080,500.76, up from CNY 246,192,999.32 year-over-year, representing an increase of about 10.9%[52] - The company’s cash flow from financing activities showed a net outflow of CNY -40,482,106.52, an improvement from CNY -55,397,382.00 in the previous year[54] - The net cash flow from investing activities was negative at CNY -762,387,980.92, compared to CNY -209,278,870.94 in the previous year, indicating a significant increase in cash outflow[54] Research and Development - Research and development expenses rose to ¥101,412,458.93, a 48% increase from ¥68,618,202.28, driven by the company's commitment to technology-driven growth[15] - Research and development expenses increased to ¥46,686,069.25, a rise of 57.5% compared to ¥29,621,198.72 in the previous period[37] - The company is focusing on enhancing its innovative drug R&D and production service system, which is expected to become a new growth point for performance[21] Shareholder Information - The company reported a total of 11,362 common shareholders at the end of the reporting period[11] - ASYMCHEM LABORATORIES, INCORPORATED held 41.69% of the shares, making it the largest shareholder[11] - The company did not engage in any repurchase transactions during the reporting period[12] Other Financial Metrics - The weighted average return on net assets was 5.02%, an increase of 0.97% compared to the previous year[7] - The company reported a significant increase in cash inflow from other operating activities, totaling CNY 36,300,531.09, compared to CNY 43,071,978.98 in the previous year, a decrease of about 16.5%[52] - The company reported an increase in other income to ¥4,413,787.50 from ¥10,873,550.90, indicating a decrease of 59.3%[39] - The company reported a total comprehensive income of CNY 250,752,408.40, up from CNY 216,212,209.76, which is an increase of about 15.9%[48]